Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson, Kathleen M. Neuzil, Cynthia G. Whitney, Patty Starkovich, Maya Dunstan, Onchee Yu, Jennifer C. Nelson, Daniel R. Feikin, David K. Shay, James Baggs, Barb Carste, Moon H. Nahm, George Carlone

Research output: Contribution to journalArticlepeer-review

Abstract

In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar ®) or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 65 years or above and at least 5 years previously. Fever was uncommon and did not vary by study group. The rate of local reactions increased with higher volumes of PCV and the rate following 2.0 ml of PCV was comparable to that following 0.5 ml PPV.

Original languageEnglish (US)
Pages (from-to)3697-3703
Number of pages7
JournalVaccine
Volume23
Issue number28
DOIs
StatePublished - May 25 2005
Externally publishedYes

Keywords

  • Conjugate vaccine
  • Pneumococcal vaccine
  • Vaccine safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine'. Together they form a unique fingerprint.

Cite this